In subgroup analysis, the rates of high EZH2 expression in breast cancer, lung cancer and CRC were 0.53 (95%CI: 0.44-0.62), 0.52 (95%CI: 0.42-0.62) and 0.55 (95%CI: 0.29-0.82), respectively. This evidence concerns the gene EZH2 and breast carcinoma.